Treatment of chronic lymphocytic leukemia
- 30 April 2004
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 31, 60-65
- https://doi.org/10.1053/j.seminoncol.2004.02.017
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemiaCancer, 2003
- Phase II study of alemtuzumab in chronic lymphoproliferative disordersCancer, 2003
- Single-Agent Rituximab as First-Line and Maintenance Treatment for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research NetworkJournal of Clinical Oncology, 2003
- Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignanciesBlood, 2003
- Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)Blood, 2002
- Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international studyBlood, 2002
- Alemtuzumab: a novel monoclonal antibodyExpert Opinion on Biological Therapy, 2001
- Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study GroupBritish Journal of Haematology, 2001
- Humanized CD52 monoclonal antibody campath‐1H as first‐line treatment in chronic lymphocytic leukaemiaBritish Journal of Haematology, 1996
- Is the CHOP Regimen a Good Treatment for Advanced CLL? Results from two Randomized Clinical TrialsLeukemia & Lymphoma, 1994